Shingles

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

7100%

+ 6 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Sharp TherapeuticsPA - Pittsburgh

3 programs

Zoster Vaccine LivePhase 4Vaccine

Zoster Vaccine, LivePhase 3Vaccine

zoster vaccine livePhase 2Vaccine

MSDIreland - Ballydine

3 programs

Zoster Vaccine LivePhase 4Vaccine

Zoster Vaccine, LivePhase 3Vaccine

zoster vaccine livePhase 2Vaccine

PfizerNEW YORK, NY

1 program

Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for InjectionPhase 1/21 trial

Active Trials

NCT05703607Terminated484Est. Sep 2025

BioNTechCA - San Diego

1 program

Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for InjectionPhase 1/2

Colorado TherapeuticsCO - Louisville

1 program

ZostavaxPhase 1

ViiV HealthcareNC - Durham

1 program

ZostavaxPhase 11 trial

Active Trials

NCT02114333Completed160Est. May 2020

Dynavax TechnologiesCA - Emeryville

2 programs

Z-1018PHASE_11 trial

Z-1018PHASE_1_21 trial

Active Trials

NCT05245838Completed150Est. Oct 2022

NCT06569823Active Not Recruiting764Est. Nov 2031

Merck & Co.RAHWAY, NJ

1 program

Zoster Vaccine LivePHASE_4Vaccine1 trial

Active Trials

NCT02624375Completed10Est. Nov 2019

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

Merck & Co.Zoster Vaccine Live

Dynavax TechnologiesZ-1018

PfizerCandidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection

Dynavax TechnologiesZ-1018

ViiV HealthcareZostavax

Clinical Trials (5)

Total enrollment: 1,568 patients across 5 trials

NCT02624375 Merck & Co.Zoster Vaccine Live

Immune Response to Shingles Vaccination

Start: Feb 2016Est. completion: Nov 201910 patients

Phase 4Completed

NCT06569823 Dynavax TechnologiesZ-1018

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

Start: Jun 2024Est. completion: Nov 2031764 patients

Phase 1/2Active Not Recruiting

NCT05703607 PfizerCandidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Start: Jan 2023Est. completion: Sep 2025484 patients

Phase 1/2Terminated

NCT05245838 Dynavax TechnologiesZ-1018

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Start: Jan 2022Est. completion: Oct 2022150 patients

Phase 1Completed

NCT02114333 ViiV HealthcareZostavax

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

Start: May 2014Est. completion: May 2020160 patients

Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

Vaccine is the dominant modality (100% of programs)

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.